{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:23:11Z","timestamp":1787728991665,"version":"build-2784847793"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012864","name":"Biomedical Research Institute of New Mexico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Toxicol."],"abstract":"<jats:p>Gadolinium-based contrast agents are commonly used to enhance magnetic resonance imaging. In 2006, Thomas Grobner identified a link between these agents and nephrogenic systemic fibrosis in patients with renal impairment. Gadolinium exposure has also been associated with acute kidney injury, skin plaques, and encephalopathy. Even in patients with normal kidney function, gadolinium may be retained in tissues for prolonged periods after contrast administration. Some patients develop persistent and varied symptoms following exposure. Although Richard Semelka and colleagues proposed the term gadolinium deposition disease, uncertainty regarding causality and pathophysiology has led to the growing adoption of the more neutral description: symptoms associated with gadolinium exposure. We describe a patient with normal renal function and Ehlos-Danlos Syndrome who developed persistent symptoms following a single gadopiclenol-enhanced magnetic resonance imaging study. Serial testing demonstrated prolonged urinary gadolinium excretion despite normal kidney function and an undetectable blood gadolinium concentration. Gadolinium remained detectable in the urine long after the expected period of elimination. The patient\u2019s clinical manifestations persisted for an extended period following exposure. We hypothesize that slow redistribution of gadolinium from retained tissue stores contributed to the prolonged urinary excretion observed in this patient. We also discuss theoretical host-susceptibility factors that may have increased her risk of gadolinium retention following gadolinium-enhanced magnetic resonance imaging. However, this case adds to the ongoing discussion regarding the clinical significance and potential mechanisms of persistent gadolinium retention in patients with normal renal function.<\/jats:p>","DOI":"10.3389\/ftox.2026.1846464","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:06:40Z","timestamp":1784167600000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A hypothesis-generating case of gadolinium retention and persistent symptoms after MRI despite normal renal function in a patient with hypermobile Ehlers-Danlos syndrome"],"prefix":"10.3389","volume":"8","author":[{"given":"Cassandra","family":"Cox","sequence":"first","affiliation":[{"name":"Kidney Institute of New Mexico, Internal Medicine, University of New Mexico Health Science Center","place":["Albuquerque, NM, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Unruh","sequence":"additional","affiliation":[{"name":"Kidney Institute of New Mexico, Internal Medicine, University of New Mexico Health Science Center","place":["Albuquerque, NM, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Wagner","sequence":"additional","affiliation":[{"name":"Kidney Institute of New Mexico, Internal Medicine, University of New Mexico Health Science Center","place":["Albuquerque, NM, United States"]},{"name":"New Mexico Veterans Affairs Healthcare System, Associate Chief of Staff Research Section","place":["Albuquerque, NM, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Patricia","family":"Escobar","sequence":"additional","affiliation":[{"name":"Kidney Institute of New Mexico, Internal Medicine, University of New Mexico Health Science Center","place":["Albuquerque, NM, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Walsh","sequence":"additional","affiliation":[{"name":"Catriona Walsh, The Food Phoenix","place":["Maghera, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia X.","family":"Jastrzemski","sequence":"additional","affiliation":[{"name":"University of New Mexico Health Science Center, University of New Mexico","place":["Albuquerque, NM, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Henderson","sequence":"additional","affiliation":[{"name":"University of New Mexico Health Science Center, University of New Mexico","place":["Albuquerque, NM, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"DeAguero","sequence":"additional","affiliation":[{"name":"Kidney Institute of New Mexico, Internal Medicine, University of New Mexico Health Science Center","place":["Albuquerque, NM, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.mri.2016.05.005","article-title":"Self-reported gadolinium toxicity: a survey of patients with chronic symptoms","volume":"1080","author":"Burke","year":"2016","journal-title":"Magn. Reson Imaging"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s10439-020-02474-4","article-title":"Targeted intravenous nanoparticle delivery: role of flow and endothelial glycocalyx integrity","volume":"48","author":"Cheng","year":"2020","journal-title":"Ann. Biomed. Eng."},{"key":"B3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3390\/genes10080609","article-title":"Cellular and molecular mechanisms in the pathogenesis of classical and hypermobile Ehlers\u2013Danlos syndrome","volume":"10","author":"Chiarelli","year":"2019","journal-title":"Genes (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.3390\/ijms25074071","article-title":"Toxicity mechanisms of gadolinium and gadolinium-based contrast agents\u2014A review","volume":"25","author":"Coimbra","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/00002281-200311000-00017","article-title":"Nephrogenic fibrosing dermopathy: the first 6 years","volume":"15","author":"Cowper","year":"2003","journal-title":"Curr. Opin. Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/00000372-200110000-00001","article-title":"Nephrogenic fibrosing dermopathy","volume":"23","author":"Cowper","year":"2001","journal-title":"Am. J. Dermatopathol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1376587","DOI":"10.3389\/ftox.2024.1376587","article-title":"The safety of magnetic resonance imaging contrast agents","volume":"6","author":"Cunningham","year":"2024","journal-title":"Front. Toxicol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1039\/b905145g","article-title":"Incorporation of excess gadolinium into human bone from medical contrast agents","volume":"1","author":"Darrah","year":"2009","journal-title":"Metallomics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/s41598-023-28666-1","article-title":"The onset of rare earth metallosis begins with renal gadolinium-rich nanoparticles from MRI contrast exposure","volume":"13","author":"DeAguero","year":"2023","journal-title":"Sci. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2215\/CJN.03921106","article-title":"Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure","volume":"2","author":"Deo","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.jid.2019.03.1145","article-title":"Nephrogenic systemic fibrosis is mediated by Myeloid C-C Chemokine Receptor 2","volume":"139","author":"Do","year":"2019","journal-title":"J. Invest Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1007\/s00204-025-04124-x","article-title":"Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role","volume":"99","author":"Domingo","year":"2025","journal-title":"Arch. Toxicol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1096\/fj.201500188R","article-title":"Centrality of bone marrow in the severity of gadolinium-based contrast-induced systemic fibrosis","volume":"30","author":"Drel","year":"2016","journal-title":"FASEB J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/ndt\/gfh272","article-title":"Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients","volume":"19","author":"Erley","year":"2004","journal-title":"Nephrol. Dial. Transpl."},{"key":"B15","unstructured":"European database of suspected adverse drug reaction reports (EudraVigilance)\n          \n          \n          2026"},{"key":"B16","unstructured":"EMA\u2019s final opinion confirms restrictions on use of linear gadolinium agents in body scans\n          \n          \n          2017"},{"key":"B17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/sj.ki.5002338","article-title":"Gadolinium and nephrogenic systemic fibrosis","volume":"72","author":"Grobner","year":"2007","journal-title":"Kidney Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"110383","DOI":"10.1016\/j.mri.2025.110383","article-title":"Precipitation of gadolinium from magnetic resonance imaging contrast agents may be the Brass tacks of toxicity","volume":"119","author":"Henderson","year":"2025","journal-title":"Magn. Reson Imaging"},{"key":"B19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1472-8206.2006.00447","article-title":"Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review","volume":"20","author":"Id\u00e9e","year":"2006","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1148\/radiol.13131669","article-title":"High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material","volume":"270","author":"Kanda","year":"2014","journal-title":"Radiology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1053\/j.ajkd.2018.10.011","article-title":"Update on the native Kidney Biopsy: core curriculum 2019","volume":"73","author":"Luciano","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ajmg.c.31552","article-title":"The 2017 international classification of the Ehlers\u2013Danlos syndromes","volume":"175","author":"Malfait","year":"2017","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1681\/ASN.2006060601","article-title":"Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging","volume":"17","author":"Marckmann","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1148\/radiol.15150025","article-title":"Intracranial gadolinium deposition after contrast-enhanced MR imaging","volume":"275","author":"McDonald","year":"2015","journal-title":"Radiology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1148\/radiol.2018181151","article-title":"Gadolinium retention: a research roadmap from the 2018 NIH\/ACR\/RSNA workshop","volume":"289","author":"McDonald","year":"2018","journal-title":"Radiology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1148\/radiol.2021211349","article-title":"Symptoms associated with Gadolinium exposure (SAGE): a suggested term","volume":"302","author":"McDonald","year":"2022","journal-title":"Radiology"},{"key":"B27","article-title":"Proteoglycans and sulfated glycosaminoglycans","volume-title":"Essentials of Glycobiology","author":"Merry","year":"2022"},{"key":"B28","doi-asserted-by":"publisher","first-page":"100105","DOI":"10.1016\/j.inpm.2022.100105","article-title":"Encephalopathy after unintentional intrathecal gadolinium: a letter to the editor","volume":"1","author":"Moradian","year":"2022","journal-title":"Interv. Pain Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/j.1365-2133.2004.05900","article-title":"Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis","volume":"150","author":"Ortonne","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"11436","DOI":"10.1021\/acs.analchem.4c06624","article-title":"Glycan-induced transchelation of gadolinium from magnetic resonance imaging contrast agent complexes","volume":"97","author":"Polewski","year":"2025","journal-title":"Anal. Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/ph10030070","article-title":"Glycosaminoglycan interactions with chemokines add complexity to a complex system","volume":"10","author":"Proudfoot","year":"2017","journal-title":"Pharm. (Basel)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00424-007-0212-8","article-title":"The endothelial glycocalyx: composition, functions, and visualization","volume":"454","author":"Reitsma","year":"2007","journal-title":"Pfl\u00fcgers Arch."},{"key":"B33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/RLI.0b013e31815a3407","article-title":"High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent","volume":"43","author":"Rydahl","year":"2008","journal-title":"Invest Radiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/RLI.0000000000000977","article-title":"Gadolinium deposition disease: current state of knowledge and expert opinion","volume":"58","author":"Semelka","year":"2023","journal-title":"Invest Radiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.mri.2016.07.016","article-title":"Gadolinium deposition disease: initial description of a disease that has been around for a while","volume":"34","author":"Semelka","year":"2016","journal-title":"Magn. Reson Imaging"},{"key":"B36","doi-asserted-by":"publisher","first-page":"107598","DOI":"10.1016\/j.intimp.2021.107598","article-title":"MCP-1: function, regulation, and involvement in disease","volume":"101","author":"Singh","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1021\/acsnano.6b06812","article-title":"The endothelial Glycocalyx controls interactions of quantum dots with the endothelium and their translocation across the blood-tissue border","volume":"11","author":"Uhl","year":"2017","journal-title":"ACS Nano"},{"key":"B38","volume-title":"FDA Adverse Event Reporting System (FAERS) Public Dashboard","year":"2026"},{"key":"B39","unstructured":"FDA drug safety communication: gadolinium retention following contrast MRI\n          \n          \n          2017"},{"key":"B40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13244-024-01763-z","article-title":"MRI contrast agents and retention in the brain: review of contemporary knowledge and recommendations","volume":"15","author":"Vymazal","year":"2024","journal-title":"Insights Imaging"},{"key":"B42","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1152\/ajprenal.00166.2016","article-title":"Pathophysiology of gadolinium-associated systemic fibrosis","volume":"311","author":"Wagner","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."}],"container-title":["Frontiers in Toxicology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/ftox.2026.1846464\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:32:17Z","timestamp":1787725937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/ftox.2026.1846464\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":41,"alternative-id":["10.3389\/ftox.2026.1846464"],"URL":"https:\/\/doi.org\/10.3389\/ftox.2026.1846464","relation":{},"ISSN":["2673-3080"],"issn-type":[{"value":"2673-3080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"article-number":"1846464"}}